[Federal Register Volume 77, Number 38 (Monday, February 27, 2012)]
[Notices]
[Pages 11560-11562]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-4376]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Model Cell Lines With and Without AKT1 Mutations Derived From Proteus
Syndrome Patients
Description of Technology: The Proteus syndrome is a congenital
disorder characterized by patchy overgrowth and hyperplasia (cell
proliferation) of multiple tissues and organs, along with
susceptibility to developing tumors. It is a rare disorder, with
incidence of less than one case per million, caused by a somatic
mutation. It is also a mosaic disorder, that is one in which cells of
the same person have different genetic content from one another. The
NHGRI inventors have generated cell lines from patients with Proteus
syndrome and discovered that a somatic activating mutation in the
serine-threonine kinase AKT1 is associated with Proteus syndrome. AKT1
is an oncogene and an enzyme known to mediate cell proliferation and
apoptosis (programmed cell death process) and has been a target for
anti-cancer therapies. A number of single-cell lines with the AKT1
mutation showing increased AKT1 phosphorylation and their matched
controls without the mutation have been generated. The cell lines can
be used to screen therapeutic targets for AKT1, for study design, as
models of Proteus syndrome and early stages of cancerous conditions.
Potential Commercial Applications
Cell lines generated from patients with Proteus syndrome.
Obtained a number of single-cell lines with the AKT1
mutation and their matched controls without the mutation.
[[Page 11561]]
Cell lines with the mutation showed increased AKT1
phosphorylation for activating mutation.
Competitive Advantages
Screening of potential therapeutics that target AKT1.
Cell lines have well-matched controls for rigorous study
design.
Serves as model cell lines of Proteus syndrome and early
stages of cancerous conditions.
Development Stage
Prototype.
Clinical.
In vivo data available (human).
Inventors: Leslie G. Biesecker and Marjorie J. Lindhurst (NHGRI).
Publication: Lindhurst MJ, et al. A mosaic activating mutation in
AKT1 associated with the Proteus syndrome. N Engl J Med. 2011 Aug
18;365(7):611-619. [PMID 21793738].
Intellectual Property: HHS Reference No. E-033-2012/0 -- Research
Tool. Patent protection is not being pursued for this technology.
Licensing Contact: Whitney Hastings, Ph.D.; 301-451-7337;
[email protected]
Non-toxic Compounds That Inhibit the Formation and Spreading of Tumors
Description of Technology: Available for licensing are novel
pyrrolopyrimidine compounds that disrupt the assembly of the
perinucleolar compartment (PNC), a sub-nuclear structure highly
prevalent in metastatic tumors. These notable compounds act without
overt cytotoxicity.
The presence of the PNC positively correlates with metastatic
capacity, making it a potential marker for cancer development and
prognosis. These compounds could also serve as useful tools to
elucidate the biology driving the formation and maintenance of the PNC,
and unravel its association with metastasis.
Potential Commercial Applications
Use in the therapeutic intervention of metastasis in
cancer.
Use as tools to elucidate the biology of the PNC.
Competitive Advantages
No existing FDA-approved treatment for the clinical
management of metastasis.
Target is specific to metastatic tumors.
Compounds are not toxic.
Broadly acting across all metastatic cancers.
Development Stage
Early-stage.
In vitro data available.
Inventors: Samarjit Patnaik et al. (NCATS).
Intellectual Property: HHS Reference No. E-276-2011/0 -- U.S.
Provisional Application No. 61/576,780 filed 16 Dec 2011.
Licensing Contact: Patrick McCue, Ph.D.; 301-435-5560;
[email protected].
Collaborative Research Opportunity: The National Center for
Advancing Translational Sciences is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize this technology. For collaboration
opportunities, please contact Lili M. Portilla, MPA at 301-217-2589 or
[email protected].
Novel Radio-Labeled Agents for Imaging Alzheimer's Disease-Associated
Amyloid
Description of Technology: This technology introduces novel radio-
labeled agents for imaging amyloid deposits in the brains of
Alzheimer's Disease patients. These are small molecule, radio-ligand
compounds that are analogs of benzo[d]thiazole. They are highly
specific to amyloid, have low background noise, do not undergo rapid
defluoridation and do not produce residual radioactivity in the brain.
In addition, the compounds are stable and may be readily synthesized
from commercially available starting materials. These compounds may be
used in many noninvasive imaging techniques including: magnetic
resonance spectroscopy (MRS) or imaging (MRI), or positron emission
tomography (PET) or single-photon emission computed tomography (SPECT)
to measure amyloid. Non-invasive detection of Alzheimer's disease-
associated amyloid plaques in the brain would be valuable for early
diagnosis, monitoring, and for clinical development of therapeutic
drugs.
Potential Commercial Applications: Imaging agents for use in
magnetic resonance spectroscopy (MRS), or imaging (MRI), positron
emission tomography (PET) or single-photon emission computed tomography
(SPECT).
Competitive Advantages: Highly specificity to amyloid, low
background, do not undergo rapid defluoridation and do not produce
residual radioactivity in the brain.
Development Stage: Early-stage.
Inventors: Lisheng Cai and Victor W. Pike (NIMH).
Publications
1. Cai L, et al. Synthesis and structure-affinity relationships of
new 4-(6-iodo-H-imidazo[1,2-a]pyridin-2-yl)-N-dimethylbenzeneamine
derivatives as ligands for human beta-amyloid plaques. J Med Chem. 2007
Sep 20;50(19):4746-4758. [PMID 17722900].
2. Cai L, et al. Synthesis and evaluation of N-methyl and S-methyl
11C-labeled 6-methylthio-2-(4'-N,N-dimethylamino)phenylimidazo[1,2-
a]pyridines as radioligands for imaging beta-amyloid plaques in
Alzheimer's disease. J Med Chem. 2008 Jan 10;51(1):148-158. [PMID
18078311].
Intellectual Property: HHS Reference No. E-225-2011/0--U.S.
Provisional Application No. 61/535,569 filed 16 Sep 2011.
Related Technology: HHS Reference No. E-156-2006/0--U.S. Patent
Application No. 12/293,340 filed 17 Sep 2008.
Licensing Contact: Tedd Fenn, J.D.; 301-435-5031;
[email protected].
Collaborative Research Opportunity: The National Institute of
Mental Health (NIMH) is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate or commercialize Beta-amyloid Imaging Agents. For
collaboration opportunities, please contact Suzanne L. Winfield, Ph.D.
at [email protected] or 301-402-4324.
A New Class of Broad-Spectrum Antibiotics: Naturally-Occurring
Chrysophaetins and Their Analogues
Description of Technology: This invention, offered for licensing
and commercial development, relates to a new class of naturally
occurring antimicrobial compounds called Chrysophaetins, and to their
synthetic analogues. Isolated from an alga species, the mechanism of
action of these compounds is through the inhibition of bacterial
cytoskeletal protein FtsZ, an enzyme necessary for the replication of
bacteria. FtsZ is responsible for Z-ring assembly in bacteria, which
leads to bacterial cell division. Highly conserved among all bacteria,
FtsZ is a very attractive antimicrobial target.
The chrysophaetin exhibits antimicrobial activity against drug
resistant bacteria, methicillin-resistant Staphylococcus aureus (MRSA)
and vancomycin-resistant Enterococcus faecalis (VRE), as well as other
drug susceptible strains. The general structure of the natural compound
is shown below:
[[Page 11562]]
[GRAPHIC] [TIFF OMITTED] TN27FE12.009
Potential Commercial Applications
Therapeutic potential for treating general and drug-
resistant bacterial infections in clinical and veterinary populations.
Antiseptics in hospital settings.
Competitive Advantages
Effective for commonly occurring drug-resistant infections
MRSA and VRE.
Broad spectrum of efficacy because mechanism of action is
against the bacterial protein FtsZ, which has similar structure in all
bacteria.
Potential for additive efficacy when combined with other
antibiotics due to distinct mechanism of action.
Other drugs with similar structure and antibacterial
properties can be synthesized using the chemical structure template
shown above.
Development Stage
Early-stage.
In vitro data available.
Inventors: Carole A Bewley, et al. (NIDDK).
Publication: Plaza A, et al. Chrysophaentins A-H, antibacterial
bisdiarylbutene macrocycles that inhibit the bacterial cell division
protein FtsZ. J Am Chem Soc. 2010 Jul 7;132(26):9069-9077. [PMID
20536175].
Intellectual Property: HHS Reference No. E-116-2010/0--PCT
Application No. PCT/US2011/026200 filed 25 Feb 2011, which published as
WO 2011/106630 on 01 Sep 2011.
Licensing Contact: John Stansberry, Ph.D.; 301-435-5236;
[email protected].
Collaborative Research Opportunity: The National Institute of
Diabetes and Digestive and Kidney Diseases, Laboratory of Bioorganic
Chemistry, is seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate, or
commercialize the chrysophaentin antibiotics. Please contact Marguerite
J. Miller at 301-451-3636 or [email protected] for more
information.
Dated: February 21, 2012.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2012-4376 Filed 2-24-12; 8:45 am]
BILLING CODE 4140-01-P